Ayala Pharmaceuticals Inc (ADXS)

[terry hallinan]

Ancient and irrelevant history

Even predecessor adjuvants Paterson's, Ignatius. are becoming workhorses of the future for Glaxo

Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant


Abstract

The development of non-infectious subunit vaccines greatly increases the safety of prophylactic immunization, but also reinforces the need for a new generation of immunostimulatory adjuvants. Because adverse effects are a paramount concern in prophylactic immunization, few new adjuvants have received approval for use anywhere in the developed world. The vaccine adjuvant monophosphoryl lipid A is a detoxified form of the endotoxin lipopolysaccharide, and is among the first of a new generation of Toll-like receptor agonists likely to be used as vaccine adjuvants on a mass scale in human populations. Much remains to be learned about this compound’s mechanism of action, but recent developments have made clear that it is unlikely to be simply a weak version of lipopolysaccharide. Instead, monophosphoryl lipid A’s structure seems to have fortuitously retained several functions needed for stimulation of adaptive immune responses, while shedding those associated with pro-inflammatory side effects.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2647720/

Doesn't non-infectius-subunit ring a bell for you like the rabies virus used to smuggle drugs across the blood-brain barrier and even the saliva of the vampire bat used for clot-busting in the brain?

I think ADXS' ancient technology is as modern as tomorrow while the new kids are continuing to get punched in the nose.

AbbVie grapples with another setback as 2 PhIII trials for its PARP veliparib flop

Up until now, PARP inhibitors have been blazing a broad, long trail of success in the clinic...

https://endpts.com/abbvie-grapples-with-another-setback-as-2-phiii-trials-for-its-parp-veliparib-flop/

Awww...

PARP inhibitors where AZN has been a star appear to becoming a trail instead of a broad super highway while AZN's prospects with its Durvalumab checkpoint inhibitor appear less than glowing at the moment:

http://www.fiercebiotech.com/biotech/astrazeneca-gives-up-durvalumab-head-and-neck-cancer-early-filing-plans

Where has Yvonne Paterson's vaccine adjuvant invention been shown to be a turkey?

Looks like a record of unparalleled success to me though not in price appreciation - yet.

JMO.

Best, Terry